I. Significance of Recombinant Protein PTMs
Post-translational modification (PTM) is a pivotal biological process that endows proteins with functional diversity via chemical alterations after protein biosynthesis, encompassing glycosylation, phosphorylation, acetylation and other categories (Figure 1). By modulating protein charge, conformational structure and molecular interaction sites, PTMs directly govern the biological activity, in vivo metabolic behavior and structural stability of recombinant proteins.
From the pharmacodynamic perspective, PTMs serve as the core for precise functional regulation. For instance, afucosylation in the Fc region of monoclonal antibodies enhances antibody-dependent cellular cytotoxicity (ADCC), while galactose content modulates complement-dependent cytotoxicity (CDC). Sialylation modification of erythropoietin shields the protein from binding to hepatic asialoglycoprotein receptors, thereby markedly prolonging its serum half-life.
In terms of pharmacokinetics, PTMs optimize drug tissue distribution and clearance profiles. PEGylated interferon achieves long-acting sustained release by covalently conjugating polyethylene glycol to reduce renal filtration. Certain glycan modifications also improve protein targeting capability and diminish non-specific tissue accumulation.
Regarding structural stability, PTMs preserve protein functional integrity by resisting enzymatic degradation and molecular aggregation. Specifically, acetylation inhibits N-terminal proteolysis, and the formation of specific disulfide bonds ensures correct folding of complex recombinant proteins.
II. Classification and Biological Functions of Recombinant Protein PTMs
Post-translational modifications constitute the core mechanism for functional maturation and diversification of recombinant proteins, which accurately regulate protein structure, biological activity and stability through targeted chemical modification. As summarized in Table 1, glycosylation stands out as the most prevalent PTM, mainly divided into N-linked and O-linked glycosylation, exerting irreplaceable effects in the development of therapeutic antibodies.
The N-glycosylation pattern of antibody Fc segments potently boosts ADCC and complement activation capacity, directly determining clinical therapeutic efficacy. Glycosylation also extends the half-life of protein drugs via steric hindrance effects. Unlike the extensive regulatory role of glycosylation, phosphorylation predominantly mediates dynamic regulation of signal transduction proteins. For example, site-specific phosphorylation of recombinant insulin analogues simulates conformational changes of native insulin to precisely activate cell membrane receptor signaling pathways.
N-terminal acetylation elevates protein stability by blocking endopeptidase-mediated hydrolysis. Notably, not all PTMs contribute to functional enhancement; ubiquitination typically labels target proteins for proteasomal degradation. In bioengineering applications, suppression of the ubiquitination pathway effectively improves intracellular stability of recombinant proteins, offering innovative strategies for intracellular delivery systems such as CRISPR-associated enzymes.
Specialized modifications including tyrosine sulfation are decisive for protein-receptor binding interactions. Tyrosine sulfation of coagulation factor VIII is an essential prerequisite for its binding to von Willebrand factor, and the absence of this modification leads to complete loss of coagulant activity.
III. Effects of Different Expression Host Systems on PTM Profiles
The PTM capacity of recombinant proteins is inherently determined by the biological characteristics of expression hosts, with distinct discrepancies in modification categories, modification accuracy and structural complexity across various systems.
As a classic prokaryotic expression platform, Escherichia coli only supports rudimentary PTM events including disulfide bond formation and N-terminal methionine excision. Lacking endoplasmic reticulum and Golgi apparatus, it is incapable of executing eukaryote-specific modifications such as glycosylation, sulfation and carboxylation. Hence, this system is merely applicable for producing non-glycosylated proteins including insulin and certain cytokines, and in vitro chemical modifications such as PEGylation are usually required to compensate for functional deficiencies.
Yeast, as a lower eukaryotic host, possesses preliminary N-glycosylation capability, yet its dominant high-mannose-type glycans differ drastically from human complex-type glycans, potentially triggering immunogenic risks. Through genetic engineering modification, yeast strains can partially recapitulate humanized glycan structures for the production of antibody fragments and vaccine antigens, whereas its performance in phosphorylation, acetylation and other modifications remains inferior to higher eukaryotic expression systems.
The baculovirus-insect cell expression system delivers more sophisticated PTM patterns. It mainly synthesizes simple-type N-glycans without sialylation modification, but supports sulfation, gamma-carboxylation and other modifications, which is well-suited for structural research of virus-like particles and membrane proteins. Nevertheless, incomplete glycan structures restrict its application in therapeutic protein manufacturing, which necessitates further optimization via in vitro enzymatic catalysis or heterologous expression of human glycosyltransferases.
Mammalian cell lines represented by CHO and HEK293 are recognized as the gold standard for authentic PTM execution. These cell lines can faithfully accomplish complex N-linked/O-linked glycosylation, hydroxyprolylation and full-spectrum phosphorylation. Furthermore, fine-tuning of glycan distribution can be realized via culture medium optimization and genome editing, complying with stringent clinical requirements for pharmaceutical homogeneity and biosafety.
In practical production, host selection requires comprehensive trade-offs between target protein PTM requirements and production costs. E. coli and yeast are preferred for structurally simple non-therapeutic proteins; insect cell systems balance manufacturing cost and eukaryotic modification potency, ideal for vaccine research and development; mammalian cell platforms guarantee high-fidelity PTM profiles for therapeutic monoclonal antibodies and coagulation factor drugs at relatively higher production costs.
IV. Quality Control Strategies for Recombinant Protein PTMs
During the regulatory submission and clinical application of recombinant protein pharmaceuticals, rigorous PTM quality control is indispensable to guarantee product safety and efficacy. Heterogeneous PTM profiles may induce inconsistent pharmacological effects and unexpected immunogenic reactions, and global regulatory authorities have established explicit specifications covering critical quality attributes and stability assessment of PTMs.
Diversified analytical techniques have been established for systematic PTM characterization. Mass spectrometry serves as the core analytical tool for accurate identification and localization of PTMs. Intact protein mass spectrometry evaluates glycan heterogeneity, while peptide mapping pinpoints N-glycosylation and phosphorylation sites. MALDI-TOF MS and hydrophilic interaction chromatography are adopted for detailed structural elucidation of released glycans.
Capillary electrophoresis (CE) and high-performance liquid chromatography (HPLC) are widely applied to analyze charge and molecular size heterogeneity. CE-SDS monitors disulfide bond integrity and proteolytic fragments, and reversed-phase HPLC assesses the chemical stability of acetylated and phosphorylated proteins. Enzyme-linked immunosorbent assay (ELISA) enables rapid high-throughput batch consistency detection of therapeutic antibodies based on glycan-specific recognition, providing real-time data support for bioprocess optimization.
In terms of structural characterization, circular dichroism (CD) spectroscopy and nuclear magnetic resonance (NMR) spectroscopy clarify the conformational impacts of PTMs. CD spectroscopy monitors secondary structural alterations induced by glycosylation, and NMR spectroscopy reveals how sulfation and hydroxyprolylation regulate local three-dimensional protein architectures, establishing the correlation between specific modifications and protein functional stability.
Conclusion
Post-translational modifications are decisive determinants of the biological activity and structural stability of recombinant proteins. The selection of appropriate expression hosts profoundly affects correct protein folding and authentic modification execution, which is fundamental to maintaining biological potency and therapeutic outcomes of recombinant protein products. Therefore, in-depth comprehension and rational optimization of PTM-related regulatory factors are of great significance for upgrading the overall quality and functional performance of recombinant protein biopharmaceuticals.
